Day: March 9, 2026

Alterity Therapeutics to Participate in the Bell Potter Healthcare Horizons Summit

Written by Customer Service on March 9, 2026. Posted in Public Companies.

MELBOURNE, Australia and SAN FRANCISCO, March 09, 2026 (GLOBE NEWSWIRE) — Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer of Alterity, will participate in the Bell Potter Healthcare Horizons Summit taking place 12-13 March 2026 in Sorrento, Australia. At the conference, Dr. Stamler will participate in a fireside chat entitled, “Optimising Late-stage Clinical Trials to Increase the Odds,” and will also host 1-on-1 investor meetings. About Alterity Therapeutics Limited Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The...

Alexander’s to Sell Rego Park I for Net Proceeds of $202 Million

Written by Customer Service on March 9, 2026. Posted in Public Companies.

PARAMUS, N.J., March 09, 2026 (GLOBE NEWSWIRE) — Alexander’s, Inc. (NYSE: ALX) announced today that it has entered into an agreement to sell its Rego Park I property to Northwell Health, Inc. The gross purchase price is $235.5 million and the net proceeds will be $202 million. The property is unencumbered. The property is located at the intersection of Queens Boulevard and Junction Boulevard, adjacent to the Long Island Expressway, in Queens, New York. The Rego Park I property is comprised of a vacant, three-story, 338,000 gross leasable square foot structure built in 1959 and a 1,236 space parking garage, located on 5.9 acres. Alexander’s recently vacated the property by relocating tenants to its adjacent Rego Park II shopping center. The financial statement gain will be approximately $147 million and the tax gain will be approximately...

Siris Agrees to Acquire a Majority Stake in TAKKION from Apollo Funds

Written by Customer Service on March 9, 2026. Posted in Mergers And Acquisitions.

Siris to partner with TAKKION to provide full life-cycle renewable energy solutions to meet the increasing demand for power WEST PALM BEACH, Fla. and CENTENNIAL, Colo., March 09, 2026 (GLOBE NEWSWIRE) — Siris (together with its affiliates, “Siris”), a leading private equity firm targeting services companies that support critical technology infrastructure, today announced a definitive agreement to acquire a majority stake in TAKKION, a premier integrated services provider to the renewable energy industry that generated approximately $600 million in revenue in 2025, from funds managed by Apollo (NYSE:APO) (the “Apollo Funds”). The transaction is expected to close in Q2 2026, subject to customary closing conditions. Founded in 2019, TAKKION is a scaled, diversified energy services platform operating in an increasingly attractive industry...

Aecon Utilities expands U.S. electrical utility services capabilities with acquisition of Duna Services and an interest in KNX Utility Services

Written by Customer Service on March 9, 2026. Posted in Mergers And Acquisitions.

TORONTO, March 09, 2026 (GLOBE NEWSWIRE) — Aecon Group Inc. (TSX: ARE) (“Aecon” or the “Company”) announced today that its subsidiary, Aecon Utilities Group Inc. (“Aecon Utilities”), has acquired Duna Services, LLC (“Duna Services”) and its subsidiaries Arc American, LLC and C.A. Advanced, LLC, and a 49% interest in KNX Utility Services, LLC (“KNX”) from Ryker Holdings Inc. for a base purchase price of US$60 million with the potential for additional contingent proceeds (the “Transaction”). The Transaction is being financed through Aecon Utilities’ standalone committed revolving credit facility. Headquartered in Wakarusa, Indiana, Duna Services and its subsidiaries have approximately 350 employees and bring 14 years of experience providing underground and overhead electrical distribution, transmission, substation maintenance, and...

Tilray Brands Acquires BrewDog Australia, Establishing Strategic Base to Accelerate Global Beverage and Consumer Products Growth Across the Asia-Pacific Region

Written by Customer Service on March 9, 2026. Posted in Mergers And Acquisitions.

Acquisition Includes BrewDog’s Profitable Australian Operations Including Brisbane Brewery and Two Flagship Bars Transaction Positions Tilray to Scale BrewDog Across Australia’s National Retail and Grocery Channels and Introduce Broader Beverage Portfolio Across Asia-Pacific NEW YORK and BRISBANE, Australia, March 09, 2026 (GLOBE NEWSWIRE) — Tilray Brands, Inc. (“Tilray”, “our”, “we” or the “Company”) (Nasdaq: TLRY; TSX: TLRY), a leading global lifestyle and consumer packaged goods company at the forefront of the beverage, cannabis and wellness industries, today announced the completion of the acquisition of BrewDog Brewing Australia Pty Ltd., including BrewDog’s Australian brewing and production facility in Brisbane, Queensland, along with a portfolio of owned and franchised BrewDog bars across Australia. Irwin D. Simon, Chairman...

Boundless Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

Written by Customer Service on March 9, 2026. Posted in Earnings Releases And Operating Results.

KOMODO-1 first-in-human clinical trial of BBI-940 open for enrollment $108 million in cash provides runway into the second half of 2028, through expected clinical proof-of-concept readout for KOMODO-1 SAN DIEGO, March 09, 2026 (GLOBE NEWSWIRE) — Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced financial results and business highlights for the fiscal quarter and full year ended December 31, 2025. “With the KOMODO-1 trial of BBI-940 actively enrolling, we are excited to evaluate this potentially first-in-class oral Kinesin degrader in patients with breast cancer who are seeking new treatment options. BBI-940 is designed to disrupt ecDNA segregation...

Editas Medicine Announces Fourth Quarter and Full Year 2025 Results and Business Updates

Written by Customer Service on March 9, 2026. Posted in Earnings Releases And Operating Results.

Lead candidate, EDIT-401, which demonstrated >90% mean LDL-C reduction in preclinical studies, remains on track for IND/CTA submission by mid-2026 Preparing to initiate Company’s first-in-human clinical trial in HeFH patients, with early human proof-of-concept data on track for year-end 2026 Strong cash position with cash runway into the third quarter of 2027 CAMBRIDGE, Mass., March 09, 2026 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today reported financial results for the fourth quarter and full year 2025 and provided business updates. “We achieved notable progress in the fourth quarter of 2025 as we advanced our mission and strategy to become a leader in in vivo gene editing,” said Gilmore O’Neill, M.B., M.M.Sc.,...

3D Systems Reports Fourth Quarter and Full Year 2025 Financial Results

Written by Customer Service on March 9, 2026. Posted in Earnings Releases And Operating Results.

ROCK HILL, S.C., March 09, 2026 (GLOBE NEWSWIRE) — 3D Systems Corporation (NYSE:DDD) announced today its financial results for the fourth quarter and full year ended December 31, 2025.Fourth quarter revenue of $106.3 million grew 16% sequentially, above guidance of 8% to 10% growth, driven by a successful ramp-up of new printer system sales and higher materials consumption For full year 2025, the Company delivered double-digit top-line growth in personalized health services and aerospace and defense markets Cost reduction and efficiency programs delivered approximately $55 million of annualized cost savings in 2025 The Company expects to continue its momentum in top-line growth and bottom-line performance in 2026 Summary of Financial Results(Unaudited) Three Months Ended Year Ended(in millions, except per...

Cartesian Therapeutics Reports Full Year 2025 Financial Results and Provides Business Update

Written by Customer Service on March 9, 2026. Posted in Earnings Releases And Operating Results.

Enrollment continues to progress in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis Phase 2 TRITON trial of Descartes-08 in dermatomyositis and antisynthetase syndrome, expected to initiate in 1H26 Phase 1/2 HELIOS pediatric trial of Descartes-08 in juvenile dermatomyositis actively enrolling Approximately $126.9 million cash, cash equivalents and restricted cash as of December 31, 2025, expected to support planned operations into mid-2027, including completion of ongoing Phase 3 AURORA trial FREDERICK, Md., March 09, 2026 (GLOBE NEWSWIRE) — Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (“we”, the “Company” or “Cartesian”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today reported financial results for the year ended December 31, 2025, and outlined recent business updates. “Building...

Constellation Software Inc. Announces Results for the Fourth Quarter and Year Ended December 31, 2025 and Declares Quarterly Dividend

Written by Customer Service on March 9, 2026. Posted in Dividend Reports And Estimates.

TORONTO, March 09, 2026 (GLOBE NEWSWIRE) — Constellation Software Inc. (TSX:CSU) (“Constellation” or the “Company”) today announced its financial results for the fourth quarter and year ended December 31, 2025 and declared a $1.00 per share dividend payable on April 15, 2026 to all common shareholders of record at close of business on March 27, 2026. This dividend has been designated as an eligible dividend for the purposes of the Income Tax Act (Canada). Please note that all dollar amounts referred to in this press release are in U.S. Dollars unless otherwise stated. The following press release should be read in conjunction with the Company’s annual Consolidated Financial Statements, prepared in accordance with IFRS Accounting Standards (“IFRS”) and our annual Management’s Discussion and Analysis for the year ended December 31,...

Day: March 9, 2026

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals